echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The second-generation new crown vaccine is here!

    The second-generation new crown vaccine is here!

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 27, the UAE Ministry of Health and Prevention approved the emergency use license for the second-generation recombinant protein COVID-19 vaccine of Sinopharm Group China Biotech


    Many people are confused: What is a second-generation vaccine? Where is the more "one" in the second generation than the first generation? After the first generation, do you still need a second-generation vaccine? To this end, a reporter from Science and Technology Daily interviewed relevant R&D units


    What is the difference between the second-generation vaccine?

    The second-generation vaccine approved for emergency use this time is classified from the technical route and belongs to the recombinant protein vaccine


    "Recombinant protein vaccine is a very mature technology, not a new technology


    Since it is not a new technology, why is it a "second generation"?

    In the first generation of antigen protein design, part of the protein of the virus prototype strain, such as the key region of the S protein of the new coronavirus, is used


    Li Qiming, the main person in charge of the R&D team and the president of Sinopharm Biotechnology Research Institute, further explained that in response to the new trend of variant strains, on the basis of the first generation of vaccines, the computational structure vaccinology technology platform is used, through molecular simulation and computational construction.


    It is understood that the second-generation immune antigens are not limited to the key areas of the new coronavirus S protein previously focused in the industry


    What's so good about the second generation?

    It is precisely because the immune escape ability of various mutation sites is fully quantitatively evaluated from the source of antigen design, the second-generation vaccine is effective against a variety of virus mutant strains


    The clinical vaccination effect in the United Arab Emirates showed that the level of neutralizing antibodies evoked by the second-generation vaccine against Omi Keron strain was significantly better than that of the control vaccine group


    "Second-generation vaccines are developed for variant strains and adopt a broad-spectrum design


    The mutation of the new coronavirus is often unexpected.


    I have received a first-generation vaccine, do I still need a second-generation vaccine?

    According to the data released by the State Council’s Joint Prevention and Control Mechanism Press Conference on December 29, China has completed the entire vaccination process of 1.


    Like reporters, many members of the public have already completed the first-generation vaccine.


    It is understood that in the UAE, which is approved for emergency use, the second-generation vaccine is used as a booster vaccination for people who have been vaccinated with two doses of the Sinopharm China Bio-New Crown Inactivated Vaccine


    Li Qiming said that based on the current data, the "inactivation + recombination" vaccination method will greatly improve the level and durability of the immune response of vaccinators


    Recent studies have also shown that the neutralizing antibody titers of testers inoculated with heterologous second-generation vaccines are higher than those in the homologous vaccine group; Keron strain) is effective, and the level of neutralizing antibody is significantly better than that of the control vaccine group


    In the face of constantly mutating new coronaviruses, higher neutralizing antibodies will be more conducive to the formation of the herd immune barrier
    .
    Relevant experts said that the new clinical data and usage data will provide strong data support for the global new crown vaccine development and vaccination strategy selection
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.